Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development and characterization of two human tumor sublines expressing high-grade resistance to the cyanoguanidine CHS 828.

Anti-cancer drugs - 1 Jan 2004

Gullbo Joachim, Lövborg Henrik, Dhar Sumeer, Lukinius Agneta, Oberg Fredrik, Nilsson Kenneth, Björkling Fredrik, Binderup Lise, Nygren Peter, Larsson Rolf

Abstract excerpt

The cyanoguanidine CHS 828 has shown promising antitumor properties and is currently in early clinical trials, although the mechanism of action still is largely unknown. In this study, resistant sublines of the histiocytic lymphoma cell line U-937 GTB and the myeloma line RPMI 8226 were developed by culturing under gradually increasing concentrations of CHS 828 until reaching 25 times the parental line EC50s. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyanides
Share to Drug Screening Assays, Antitumor

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Electrophoresis, Gel, Two-Dimensional

Share to Guanidines

Share to Lymphoma, Large B-Cell, Diffuse

Share to Microscopy, Electron

Share to Multiple Myeloma

Share to Tritium

Source

Identifiers

PMID: 15090743
DOI: 10.1097/00001813-200401000-00008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development and characterization of two human tumor sublines expressing high-grade resistance to the cyanoguanidine CHS 828.PMID 15090743Read ↗

Creation of zebularine-resistant human cytidine deaminase mutants to enhance the chemoprotection of hematopoietic stem cells.Semantic proximity Read ↗

Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.Semantic proximity Read ↗

Antiproliferative and phenotype-transforming antitumor agents derived from cysteine.Semantic proximity Read ↗

V79 Chinese hamster lung cells resistant to the bis-alkylator bizelesin are multidrug-resistant.Semantic proximity Read ↗

Mutation E522K in human DNA topoisomerase IIbeta confers resistance to methyl N-(4'-(9-acridinylamino)-phenyl)carbamate hydrochloride and methyl N-(4'-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide but hypersensitivity to etoposide.Semantic proximity Read ↗

Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.Semantic proximity Read ↗

In vivo development and in vitro characterization of a subclone of murine P388 leukemia resistant to bis(diphenylphosphine)ethane.Semantic proximity Read ↗

Membrane Association of the Short Transglutaminase Type 2 Splice Variant (TG2-S) Modulates Cisplatin Resistance in a Human Hepatocellular Carcinoma (HepG2) Cell LineSemantic proximity Read ↗

Mutations in adenosine deaminase-like (ADAL) protein confer resistance to the antiproliferative agents N6-cyclopropyl-PMEDAP and GS-9219.Semantic proximity Read ↗

Elimination of chemoresistant myeloma clonogenic cells from human bone marrow by monoclonal antibody and complement.Semantic proximity Read ↗

Antineoplastic Agents, 256. Cell Growth Inhibitory Isocarbostyrils from HymenocallisSemantic proximity Read ↗

Multidrug resistance phenotype associated with selection of an aminopterin resistant dog kidney cell line.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.